Insights

Strategic collaborations Leverage Akashi’s history of partnerships with Grünenthal and Processa Pharmaceuticals to position co-development and licensing opportunities for HT-100 and DT-200, targeting fibrosis, inflammation, and DMD indications in collaboration models.

Rare disease focus Target stakeholders in Duchenne muscular dystrophy and other rare pediatric diseases where Akashi’s anti-inflammatory and anti-fibrotic assets may address high-need, under-served patient populations, enabling niche market entry strategies.

Early-stage leverage With HT-100 in early-stage development and a SARM candidate DT-200, pursue opportunities for research collaboration, milestone-driven financings, and joint-venture structures with mid-to-large biopharma seeking muscle regeneration assets.

Strategic funding signals Note the modest funding and revenue levels alongside a track record of high-profile partnerships; propose services or financing arrangements that align with early-stage biotech needs, such as milestone-based licensing, grant support, or venture co-investments.

Global licensing potential Capitalize on past exclusive licensing activity to propose international licensing or regional development deals, targeting fibrosis and inflammation pathways where HT-100 showed interest, and expand into scleroderma and related conditions.

Similar companies to Akashi Therapeutics, Inc.

Akashi Therapeutics, Inc. Tech Stack

Akashi Therapeutics, Inc. uses 8 technology products and services including W3 Total Cache, RSS, WordPress, and more. Explore Akashi Therapeutics, Inc.'s tech stack below.

  • W3 Total Cache
    Caching
  • RSS
    Content Management System
  • Content Management System
  • yepnope.js
    Javascript Frameworks
  • Modernizr
    Javascript Libraries
  • Really Simple SSL & Security
    Security
  • MediaElement.js
    Video Players
  • OpenResty
    Web Servers

Media & News

Akashi Therapeutics, Inc.'s Email Address Formats

Akashi Therapeutics, Inc. uses at least 1 email format:
Akashi Therapeutics, Inc. Email FormatsExamplePercentage
FLast@akashirx.comJDoe@akashirx.com
100%

Frequently Asked Questions

What is Akashi Therapeutics, Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact Akashi Therapeutics, Inc.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Akashi Therapeutics, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Akashi Therapeutics, Inc.'s official website is akashirx.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Akashi Therapeutics, Inc. generate?

Minus sign iconPlus sign icon
As of November 2026, Akashi Therapeutics, Inc.'s annual revenue is estimated to be <$1M.

What is Akashi Therapeutics, Inc.'s SIC code and NAICS code?

Minus sign iconPlus sign icon
Akashi Therapeutics, Inc.'s SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Akashi Therapeutics, Inc. have currently?

Minus sign iconPlus sign icon
As of November 2026, Akashi Therapeutics, Inc. has approximately 3 employees across 2 continents, including Asia and North America. Key team members include Chief Executive Officer: M. B. and Chief Scientific Officer: E. B. Explore Akashi Therapeutics, Inc.'s employee directory with LeadIQ.

What industry does Akashi Therapeutics, Inc. belong to?

Minus sign iconPlus sign icon
Akashi Therapeutics, Inc. operates in the Biotechnology Research industry.

What technology does Akashi Therapeutics, Inc. use?

Minus sign iconPlus sign icon
Akashi Therapeutics, Inc.'s tech stack includes W3 Total Cache, RSS, WordPress, yepnope.js, Modernizr, Really Simple SSL & Security, MediaElement.js and OpenResty.

What is Akashi Therapeutics, Inc.'s email format?

Minus sign iconPlus sign icon
Akashi Therapeutics, Inc.'s email format typically follows the pattern of FLast@akashirx.com. Find more Akashi Therapeutics, Inc. email formats with LeadIQ.

How much funding has Akashi Therapeutics, Inc. raised to date?

Minus sign iconPlus sign icon
As of November 2026, Akashi Therapeutics, Inc. has raised $1.5M in funding. The last funding round occurred on Jul 03, 2014 for $1.5M.

When was Akashi Therapeutics, Inc. founded?

Minus sign iconPlus sign icon
Akashi Therapeutics, Inc. was founded in 2010.
Akashi Therapeutics, Inc. logo

Akashi Therapeutics, Inc.

Biotechnology ResearchMassachusetts, United States2-10 Employees

Akashi Therapeutics is a clinical-stage biotechnology company focused on developing therapies for Duchenne muscular dystrophy and other rare diseases. Its lead program, HT-100, targets fibrosis and inflammation while supporting healthy muscle regeneration, and a second candidate, DT-200, is a selective androgen receptor modulator aimed at increasing muscle mass and strength. The company traces its origins to a collaboration between Halo Therapeutics and Dart Therapeutics, formed with input from patient advocacy groups and biotechnology veterans, and it is guided by a team experienced in drug development. 

Based in Cambridge, Massachusetts, Akashi operates as a small biotechnology team within the research sector. Its focus is on therapies for Duchenne muscular dystrophy and other rare pediatric diseases. In 2019, Akashi entered into an exclusive worldwide license with Processa Pharmaceuticals to develop and commercialize HT-100, reflecting early collaboration with external partners.

Section iconCompany Overview

Phone number
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2010
Employees
2-10

Section iconFunding & Financials

  • $1.5M

    Akashi Therapeutics, Inc. has raised a total of $1.5M of funding over 1 rounds. Their latest funding round was raised on Jul 03, 2014 in the amount of $1.5M as a Venture Round.

  • <$1M

    Akashi Therapeutics, Inc.'s revenue is estimated to be in the range of <$1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.